We are live on ! Find out more
BBA

Baker Bros. Advisors Portfolio holdings

AUM $17.4B
1-Year Est. Return 131.5%
This Fund
S&P 500
This Quarter Est. Return
+6.01%
1 Year Est. Return
+131.5%
3 Year Est. Return
+336.81%
5 Year Est. Return
+553.16%
10 Year Est. Return
+4,134.93%
AUM
$9.04B
AUM Growth
-$325M
Cap. Flow
-$209M
Cap. Flow %
-2.31%
Top 10 Hldgs %
81.82%
Holding
98
New
4
Increased
11
Reduced
16
Closed
9

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$78.4M
2
PCVX icon
Vaxcyte
PCVX
+$47.3M
3
INSM icon
Insmed
INSM
+$28.6M
4
IMCR icon
Immunocore
IMCR
+$24.2M
5
CELC icon
Celcuity
CELC
+$17.9M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$171M
2
CRSP icon
CRISPR Therapeutics
CRSP
+$27.7M
3
KRYS icon
Krystal Biotech
KRYS
+$26.6M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$26.6M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$24.5M

Sector Composition

Rank Sector Weight
1 Healthcare 98.87%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ROIV icon
26
Roivant Sciences
ROIV
$23.6B
$38M 0.42%
3,767,773
– –
IMTX icon
27
Immatics
IMTX
$1.23B
$32.8M 0.36%
7,275,830
– –
STOK icon
28
Stoke Therapeutics
STOK
$1.84B
$30.8M 0.34%
4,633,838
– –
CERS icon
29
Cerus
CERS
$575M
$26.9M 0.3%
19,351,087
-126,252
-0.6% -$211K
PCVX icon
30
Vaxcyte
PCVX
$7.65B
$24.2M 0.27%
640,885
+592,000
+1,211% +$47.3M
GLUE icon
31
Monte Rosa Therapeutics
GLUE
$1.82B
$22.8M 0.25%
4,916,095
– –
CRSP icon
32
CRISPR Therapeutics
CRSP
$4.69B
$22.3M 0.25%
654,099
-653,912
-50% -$27.7M
AKRO
33
DELISTED
Akero Therapeutics
AKRO
$22.2M 0.25%
548,713
-548,369
-50% -$23.2M
SERA icon
34
Sera Prognostics
SERA
$83.8M
$20.2M 0.22%
5,498,170
+63,771
+1% +$325K
CNTA
35
DELISTED
Centessa Pharmaceuticals
CNTA
$17.6M 0.2%
1,227,178
– –
NGNE icon
36
Neurogene
NGNE
$670M
$17.4M 0.19%
1,486,200
+811,750
+120% +$14.1M
IDYA icon
37
IDEAYA Biosciences
IDYA
$3.42B
$17.4M 0.19%
1,062,123
– –
VRNA
38
DELISTED
Verona Pharma
VRNA
$14.2M 0.16%
+223,843
New +$13.4M
CADL icon
39
Candel Therapeutics
CADL
$688M
$13.8M 0.15%
2,437,189
-544,794
-18% -$4.45M
PRAX icon
40
Praxis Precision Medicines
PRAX
$8.11B
$12.6M 0.14%
331,533
– –
TSVT
41
DELISTED
2seventy bio
TSVT
$12.3M 0.14%
2,497,526
– –
XENE icon
42
Xenon Pharmaceuticals
XENE
$6.1B
$11.7M 0.13%
347,408
-646,271
-65% -$24.5M
BCAX
43
Bicara Therapeutics
BCAX
$1.7B
$10.9M 0.12%
833,333
– –
IONS icon
44
Ionis Pharmaceuticals
IONS
$8.93B
$10.8M 0.12%
357,915
– –
DBVT
45
DBV Technologies
DBVT
$816M
$9.97M 0.11%
1,461,425
– –
ALMS
46
Alumis Inc
ALMS
$3.36B
$9.59M 0.11%
1,562,500
– –
MRUS
47
DELISTED
Merus
MRUS
$9.41M 0.1%
223,500
-226,500
-50% -$9.88M
PRLD icon
48
Prelude Therapeutics
PRLD
$375M
$7.78M 0.09%
10,123,824
– –
VERV
49
DELISTED
Verve Therapeutics
VERV
$7.73M 0.09%
1,691,530
– –
RCKT icon
50
Rocket Pharmaceuticals
RCKT
$342M
$7.32M 0.08%
1,097,079
+1,000,000
+1,030% +$9.88M
1
2
3 4

Similar funds

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
BCIM
British Columbia Investment Management Victoria, British Columbia, Canada $17B AUM 31.69% 1-Year Est. Return

Baker Bros. Advisors's Q1 2025 Portfolio in Review

As of Q1 2025, Baker Bros. Advisors held 98 positions worth $9.04B, down 3.5% from $9.36B the previous quarter. Its ten largest holdings account for 82% of the portfolio.

Baker Bros. Advisors's Q1 2025 filing shows 4 new, 11 increased, 16 reduced and 9 closed positions. Its largest new stake was Verona Pharma: 223,843 shares worth $14.2M. The largest sale was BeOne Medicines Ltd, an estimated $171M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 99% a quarter earlier, followed by Financials.

  • Baker Bros. Advisors's largest Q1 2025 buy was Verona Pharma: 223,843 shares worth $14.2M.
  • Baker Bros. Advisors added most to Immunovant in Q1 2025, an estimated $78.4M increase.
  • Baker Bros. Advisors's biggest Q1 2025 reduction was BeOne Medicines Ltd, cutting an estimated $171M.
  • Baker Bros. Advisors fully exited Krystal Biotech in Q1 2025, selling an estimated $26.6M.
  • Baker Bros. Advisors's ten largest holdings make up 82% of its $9.04B portfolio in Q1 2025.
  • Baker Bros. Advisors opened 4 new positions and closed 9 in Q1 2025.
  • Baker Bros. Advisors's portfolio value fell 3.5% quarter-over-quarter to $9.04B.

Based on Baker Bros. Advisors's 13F filing for Q1 2025, filed 15 May 2025.